Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells Journal Article

  


Authors: Bocchia, M.; Xu, Q.; Wesley, U.; Xu, Y.; Korontsvit, T.; Loganzo, F.; Albino, A. P.; Scheinberg, D. A.
Article Title: Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells
Abstract: The NB4 cell line, established from a patient with APL, carries the t(15;17) and undergoes differentiation along the granulocytic pathway when exposed to retinoic acid (RA). The NB4 cell line was used as a model for exploring the expression of genes and proteins implicated in growth regulation, differentiation and apoptosis during treatment with RA. NB4 cells undergo a series of cytological and molecular alterations during RA treatment. Day 1: cell differentiation marked by an increase in CD11b is evident. Day 2: WAF1/p21 mRNA and then protein rise, though they drop 2 days later. Day 3: the percentage of cells in S phase begins to decrease and G1 arrest begins. Day 4: p53 mRNA level and then protein levels fall. Day 5: CD11b/BCL-2 double staining cells are markedly reduced. No signs of apoptosis were observed after up to 8 days of treatment with RA. These results demonstrate that NB4 cells treated with RA rapidly differentiate and arrest at G1 phase concurrent with p53-independent WAF1/p21 induction; in addition, phenotypic differentiation appears to commence before changes in cell cycle progression. An explanation for the decrease in p53 as well as the lack of apoptosis immediately after BCL-2 downregulation will require further study.
Keywords: controlled study; human cell; antigen expression; cell cycle; cell cycle s phase; cell division; protein bcl 2; apoptosis; cell line; cell differentiation; transcription, genetic; tumor cells, cultured; protein p53; time factors; gene expression regulation; tumor suppressor gene; leukemia, promyelocytic, acute; gene expression regulation, neoplastic; kinetics; messenger rna; enzyme inhibitors; rna, messenger; cd11b antigen; acute myeloblastic leukemia; tumor suppressor protein p53; antigens, cd; cyclin-dependent kinase inhibitor p21; cyclins; cyclin dependent kinase inhibitor; proto-oncogene proteins c-bcl-2; retinoic acid; cell cycle g1 phase; burkitt lymphoma; p53; genes, p53; protein synthesis regulation; promyelocyte; bcl-2; mitosis inhibition; tretinoin; chromosome translocation 17; granulopoiesis; genes, bcl-2; humans; human; priority journal; article; macrophage-1 antigen; nb4 cells; chromosome translocation 15; waf1/p21
Journal Title: Leukemia Research
Volume: 21
Issue: 5
ISSN: 0145-2126
Publisher: Elsevier Ltd  
Date Published: 1997-05-01
Start Page: 439
End Page: 447
Language: English
DOI: 10.1016/s0145-2126(96)00085-9
PUBMED: 9225073
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030852977&doi=10.1016%2fS0145-2126%2896%2900085-9&partnerID=40&md5=33ed23412fa4b595797b26ce0aa6d0d7
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Umadevi Wesley
    7 Wesley
  2. David Scheinberg
    499 Scheinberg
  3. Tatyana Korontsvit
    53 Korontsvit
  4. Yang Xu
    6 Xu
  5. Anthony P. Albino
    111 Albino
  6. Monica Bocchia
    11 Bocchia
  7. Frank Loganzo Jr
    15 Loganzo
Related MSK Work